Heyholder
‹ Activism Filings

Chong Kun Dang Pharmaceutical Corp. Q3 operating profit KRW 22.0 billion on revenue of KRW 434.3 billion

Chong Kun Dang Pharmaceutical Corp.· Periodic Report

AI summary · Not investment advice

Jong Kun Dang sold KRW 434.3 billion worth in Q3 and earned KRW 22.0 billion from its main business, up 5.1% from a year earlier and up 18.5% from the prior quarter.

Operating profit · 3 months

KRW 22.0 billion

Key facts

Revenue (3 months)
KRW 434.3 billion
Net income (3 months)
KRW 19.3 billion
Period
Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
Revenue (prior-year 3 months)
KRW 429.8 billion
Revenue (year to date)
KRW 1.4 trillion
Operating profit (prior-year 3 months)
KRW 21.0 billion
Operating profit (year to date)
KRW 54.7 billion
Net income (prior-year 3 months)
KRW 20.2 billion
Net income (year to date)
KRW 52.4 billion

Commentary

AI commentary · Not investment advice

What happened

Chong Kun Dang reported its consolidated results for the third quarter, covering July to September. Sales for the 3 months were KRW 434.28 billion. That is 1.0% above the same 3 months a year earlier (KRW 429.82 billion) and 9.2% below the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the 3 months was KRW 22.05 billion. That is 5.1% above a year earlier (KRW 20.99 billion) and 18.5% above the previous quarter.

What changes for shareholders

Net income (final profit after taxes and other costs) for the 3 months was KRW 19.32 billion. That is 4.5% below a year earlier (KRW 20.23 billion) and 5.4% below the previous quarter.

For the year to date, from January to September, sales were KRW 1,360.51 billion. Operating profit was KRW 54.75 billion. Net income was KRW 52.36 billion.

Comments

No comments yet

Comments from shareholders will appear here.